| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Products Intro: |
Product Name:PF-06761281
CAS:1854061-19-0
Purity:>=97% (HPLC) Package:25MG Remarks:PZ0318-25MG
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Email: |
sales@dcchemicals.com |
| Products Intro: |
Product Name:PF-06761281
CAS:1854061-19-0
Purity:98% HPLC Package:100mg，250mg，1g
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Email: |
marketing1@energy-chemical.com |
| Products Intro: |
Product Name:PF-06761281 >=97% (HPLC)
CAS:1854061-19-0
Purity:NULL Package:25mg;5mg Remarks:NULL
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:PF-06761281
CAS:1854061-19-0
Purity:98% Package:100 mg；200 mg
|
|
| | PF-06761281 Basic information |
| Product Name: | PF-06761281 | | Synonyms: | PF-06761281;PF-06761281 >=97% (HPLC);Butanedioic acid, 2-hydroxy-2-[2-(2-methoxy-5-methyl-3-pyridinyl)ethyl]-, (2R)- | | CAS: | 1854061-19-0 | | MF: | C13H17NO6 | | MW: | 283.28 | | EINECS: | | | Product Categories: | | | Mol File: | 1854061-19-0.mol |  |
| | PF-06761281 Chemical Properties |
| Boiling point | 469.7±45.0 °C(Predicted) | | density | 1.358±0.06 g/cm3(Predicted) | | storage temp. | -20°C | | pka | 3.37±0.28(Predicted) | | form | powder | | color | white to beige |
| RIDADR | UN 2811 6.1 / PGIII |
| | PF-06761281 Usage And Synthesis |
| Uses | PF-06761281 has been used as a SLC13A family inhibitor, in rats to determine its unbound partition coefficient (Kpuu), to estimate its potency as a drug. | | General Description | PF-06761281 is a small, polar dicarboxylate compound. Its structure is similar to citrate, which is the endogenous substrate of Na+-citrate cotransporter (NaCT). It is a novel, potent inhibitor of SLC13a2/3/5 (solute channel) family, along with selectivity for NaCT. | | Biochem/physiol Actions | PF-06761281 is an inhibitor of the sodium-coupled citrate transporter (NaCT or SLC13A5), which may be a target for tretment and prevention of metabolic disorders. The SLC13 transporters SLC13A2 (NaDC1), SLC13A3 (NaDC3), and SLC13A5 (NaCT) co-transport di- and tricarboxylates with multiple sodium ions into cells. PF-06761281 inhibits citrate uptake with an IC50 of 740 nM for NaCT in human hepatocytes. PF-06761281 has >25-fold in vitro selectivity for NaCT over NaDC1 and NaDC3 and was inactive in a selectivity panel of 65 targets. |
| | PF-06761281 Preparation Products And Raw materials |
|